Subsequently, TACAs have been coupled with polysaccharides (zwitterionic polysaccharide, PS A1) [6], Toll-like receptor 2 (TLR2) ligand, Pam3CysSerK4 [7], and T-cell peptide epitopes [8], among others, to develop partially to fully synthetic, self-adjuvating, multi-component cancer vaccines. This evidence concerns the gene TLR2 and cancer.